Stock Track | Trevi Therapeutics Soars 5.93% as Multiple Analysts Reaffirm Buy Ratings and Raise Price Targets

Stock Track11-14

Trevi Therapeutics, Inc. (TRVI) shares surged 5.93% in pre-market trading on Friday, following a series of bullish analyst reports that reaffirmed Buy ratings and raised price targets for the company.

Leading the positive sentiment, Oppenheimer analyst Leland Gershell maintained a Buy rating on Trevi Therapeutics and increased the price target to $24 from $23. This was closely followed by Cantor Fitzgerald analyst Joshua Schimmer, who reiterated a Buy rating with a price target of $25. Additionally, Clear Street analyst Kaveri Pohlman maintained a Buy rating with a price target of $21.

The wave of optimistic analyst views suggests growing confidence in Trevi Therapeutics' potential and future prospects. Investors appear to be responding positively to these endorsements, driving the stock's significant pre-market rally. As the market opens, all eyes will be on Trevi Therapeutics to see if this momentum can be sustained throughout the trading session.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1172828492?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-14 22:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1172828492","market":"sg","top_or_hot":-1,"title":"Stock Track | Trevi Therapeutics Soars 5.93% as Multiple Analysts Reaffirm Buy Ratings and Raise Price Targets","media":"Stock Track","content":"<p>Trevi Therapeutics, Inc. (TRVI) shares surged 5.93% in pre-market trading on Friday, following a series of bullish analyst reports that reaffirmed Buy ratings and raised price targets for the company.</p>\n\n<p>Leading the positive sentiment, Oppenheimer analyst Leland Gershell maintained a Buy rating on Trevi Therapeutics and increased the price target to $24 from $23. This was closely followed by Cantor Fitzgerald analyst Joshua Schimmer, who reiterated a Buy rating with a price target of $25. Additionally, Clear Street analyst Kaveri Pohlman maintained a Buy rating with a price target of $21.</p>\n\n<p>The wave of optimistic analyst views suggests growing confidence in Trevi Therapeutics' potential and future prospects. Investors appear to be responding positively to these endorsements, driving the stock's significant pre-market rally. As the market opens, all eyes will be on Trevi Therapeutics to see if this momentum can be sustained throughout the trading session.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Trevi Therapeutics Soars 5.93% as Multiple Analysts Reaffirm Buy Ratings and Raise Price Targets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Trevi Therapeutics Soars 5.93% as Multiple Analysts Reaffirm Buy Ratings and Raise Price Targets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-14 22:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Trevi Therapeutics, Inc. (TRVI) shares surged 5.93% in pre-market trading on Friday, following a series of bullish analyst reports that reaffirmed Buy ratings and raised price targets for the company.</p>\n\n<p>Leading the positive sentiment, Oppenheimer analyst Leland Gershell maintained a Buy rating on Trevi Therapeutics and increased the price target to $24 from $23. This was closely followed by Cantor Fitzgerald analyst Joshua Schimmer, who reiterated a Buy rating with a price target of $25. Additionally, Clear Street analyst Kaveri Pohlman maintained a Buy rating with a price target of $21.</p>\n\n<p>The wave of optimistic analyst views suggests growing confidence in Trevi Therapeutics' potential and future prospects. Investors appear to be responding positively to these endorsements, driving the stock's significant pre-market rally. As the market opens, all eyes will be on Trevi Therapeutics to see if this momentum can be sustained throughout the trading session.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TRVI","symbol_name":"Trevi Therapeutics Inc.","start_time":0,"source_url":"","article_id":"1172828492","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1172828492","pubTimestamp":1763130753,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Trevi Therapeutics, Inc. (TRVI) shares surged 5.93% in pre-market trading on Friday, following a series of bullish analyst reports that reaffirmed Buy ratings and raised price targets for the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TRVI":"Trevi Therapeutics Inc."},"translate_title":"个股追踪|多位分析师重申买入评级并上调目标价Trevi Therapeutics大涨5.93%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TRVI":1},"content_text":"Trevi Therapeutics, Inc. (TRVI) shares surged 5.93% in pre-market trading on Friday, following a series of bullish analyst reports that reaffirmed Buy ratings and raised price targets for the company.\nLeading the positive sentiment, Oppenheimer analyst Leland Gershell maintained a Buy rating on Trevi Therapeutics and increased the price target to $24 from $23. This was closely followed by Cantor Fitzgerald analyst Joshua Schimmer, who reiterated a Buy rating with a price target of $25. Additionally, Clear Street analyst Kaveri Pohlman maintained a Buy rating with a price target of $21.\nThe wave of optimistic analyst views suggests growing confidence in Trevi Therapeutics' potential and future prospects. Investors appear to be responding positively to these endorsements, driving the stock's significant pre-market rally. As the market opens, all eyes will be on Trevi Therapeutics to see if this momentum can be sustained throughout the trading session.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1172828492","isCrawlerRequest":true}